Evidence Constraints
Cross-source consensus on Evidence Constraints from 1 sources and 5 claims.
1 sources · 5 claims
Risks & contraindications
Evidence quality
Highlighted claims
- No formal quantitative sensitivity analysis was conducted. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- The main limitations arose from national evidence gaps rather than the toolkit itself. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- Locally generated epidemiological and economic evidence was limited. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- Adult RSV and pneumococcal disease burden data were incomplete. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- Long-term budget impact estimation was uncertain because of macroeconomic instability. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030